The interplay between comorbidity, age and performance status (PS) as predictors of outcome in advanced colorectal cancer (ACRC) is poorly understood. We examined these factors as predictors of treatment toxicity and outcome in cetuximab-treated patients with ACRC.
introduction
Colorectal cancer is a common malignancy and represents the third most common malignancy and the second leading cause of cancer-related mortality in North America [1, 2] . While the age of onset varies, it is predominantly diagnosed in older patients. The median age at diagnosis is 71 years; 65% of patients will be ‡65 years at diagnosis and 40% will be ‡75 years [3] . The median age at death for colorectal cancer patients is 75 years, with 74% of deaths occurring in patients 65 years or older [3] . While the incidence of colorectal cancer in Western nations is expected to increase in the next three to four decades due to a demographic shift with an increase in older patients as a proportion of the whole population [4] , older patients remain underrepresented in cancer treatment trials [5] [6] [7] . In this older population in whom comorbidities are more common, little is known about the potential risks and benefits of treatment, particularly in those over the age of 80 years. Those elderly patients who are included in clinical trials tend to be free of significant comorbidity and thus may not be representative of their peers [8, 9] .
For patients with metastatic colorectal cancer and good performance status (PS), the 5-year survival rate is 10% in patients treated with chemotherapy with or without the addition of targeted agents [10] [11] [12] [13] . For treated elderly patients with good PS, there is evidence of both efficacy and acceptable toxicity suggesting age alone should not be used to influence decisions regarding treatment [8, [14] [15] [16] [17] [18] . However, evidence suggests that PS, comorbidities and perhaps social factors are relevant in predicting the results of treatment in the elderly [8, 16, 19] .
Several methods have been developed to measure comorbidity in patients with cancer [20] [21] [22] . Among these, the most widely used is the Charlson Comorbidity Index (CCI) which, although developed in general medical patients, has been validated and found to have prognostic significance in patients with cancer including colorectal cancer [23] [24] [25] . The index includes 19 medical conditions weighted 1-6 based on the associated relative risk of death within 12 months; the sum of the weighted conditions is calculated to provide a total comorbidity score [23, 24] .
The interplay between age, comorbidity and PS in predicting outcome in colorectal cancer is poorly understood. In this study, this relationship was examined as part of the prospectively randomized NCIC Clinical Trials Group CO.17 clinical trial, which compared the use of cetuximab and best supportive care (BSC) with BSC alone in patients with previously treated colorectal cancer. In particular, we examined whether age and/or comorbidity are independently predictive of treatment outcome and toxicity.
patients and methods patients
Five hundred and seventy-two patients with metastatic colorectal cancer with epidermal growth factor receptor immunohistochemically detectable were randomly assigned to receive cetuximab plus BSC or BSC alone. All patients had previously received fluoropyrimidine chemotherapy, 96% had previously received irinotecan and 98% had previously received oxaliplatin. Patients were randomly assigned to receive cetuximab (400 mg/m 2 initial dose followed by a weekly dose of 250 mg/m 2 ) plus BSC (n = 287) or BSC alone (n = 285). Treatment was continued until death, unacceptable adverse events, tumor progression, worsening symptoms of cancer or request for discontinuation by the patient [26] . The primary analysis has been reported, demonstrating that cetuximab improved overall and progression-free survival, objective tumor response rate [26] and better-preserved quality of life compared with BSC alone [27] .
comorbidity, toxicity and response to therapy A CCI score was determined for each patient by two physician reviewers using baseline medical conditions and medications. After cooperative scoring of an initial cohort of 20 patient charts to establish internal consistency, the remainder of the patient charts were scored independently with scoring discrepancies resolved by consensus. Prior diagnosis of venous thromboembolism (VTE) was also specifically recorded by reviewers. As part of data collection during the conduct of the trial, adverse events were graded using the National Cancer Institute Common Toxicity Criteria (CTC) toxicity scale, version 2. PS was graded using the Eastern Cooperative Oncology Group (ECOG) scale. Objective response was evaluated using the modified RECIST.
statistical analysis
Overall survival (OS) was defined as the time from randomization until death from any cause. Progression-free survival was defined as the time from randomization until the first objective observation of disease progression or death from any cause. As noted above, objective responses were defined according to the modified RECIST criteria. Quality of life was assessed by the European Organization for Research and Treatment of Cancer QLQ-C30 with mean changes in scores of physical function and global health status as primary endpoints.
Variables of patient age and CCI score were dichotomized; age <65 versus ‡65 years (determined prospectively as a prespecified prognostic factor in the CO.17 study protocol) and CCI score 0 versus ‡1, with higher scores indicating greater comorbidity. The chi-square test was used to perform univariate analyses for the association between age groups and baseline patient and disease and treatment characteristics such as gender, PS, site of primary, time from diagnosis to randomization, body mass index, hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine clearance and K-ras status. Logistic regression modeling was used to perform multivariate analyses (MVAs) to identify independent characteristics correlated with age. Similar analyses were carried out for the association between comorbidity groups and baseline patient, disease and treatment characteristics and to identify independent characteristics associated with comorbidity. Univariate analysis and MVA of OS and progression-free survival by age and comorbidity were carried out using log-rank tests and Cox regression models, respectively. Univariate analysis and MVA of response by age and comorbidity were carried out using Fisher's exact test and logistical regression model, respectively.
results baseline age and comorbidity scoring
Of the 572 patients included in the analysis, 41% were ‡65 years old and 25% had comorbidities at baseline. The CCI score was 1 in 21% and ‡2 in 4%. Discrepancies in the CCI score between investigators occurred in 34 charts for an interobserver agreement rate of 94%. The majority of discrepancies involved the presence or absence of connective tissue diseases, chronic respiratory disorders, diabetes or myocardial infarction.
association between age and comorbidity and other baseline characteristics
In univariate analysis, gender, number of previous chemotherapy drug classes and comorbidity scores were significantly associated with age. In MVA, hemoglobin level, number of previous chemotherapy drug regimens and comorbidity scores were independently associated with age (Table 1) . Only older age was significantly associated with greater comorbidity scores in both univariate analysis (P = 0.002) and MVA (P = 0.008) ( Table 2) .
age, comorbidity, PS, VTE and OS
Age was not significantly associated with OS in either univariate analysis [hazard ratio (HR) 1.05 for ‡65 versus <65 years with 95% confidence interval (CI) 0.87-1.27; P = 0.60, Figure 1 ] or MVA (HR 1.21 for ‡65 versus <65 years with 95% CI 0.95-1.55; P = 0.13). OS was significantly different between the two comorbidity groups (CCI score ‡1 versus 0) in univariate analysis with better survival for patients with higher comorbidity scores (HR 0.80 with 95% CI 0.65-1.00; P = 0.047, Figure 2 ). A trend toward significance was seen in MVA (HR 0.76 with 95% CI 0.57-1.02; P = 0.07, Table 3 ). A significant association between comorbidity score and OS was found in both univariate analysis (HR 0.66 for CCI score ‡1 versus Other factors significantly associated with better OS in MVA included 2 years or longer from diagnosis to randomization (P < 0.0001), LDH at or lower than upper normal limit (P = 0.04), ALP at or lower than upper normal limit (P < 0.0001), CTC grade 0 of hemoglobin (P < 0.0001), wild-type K-ras status (P = 0.002) [26] [27] [28] and cetuximab treatment (P = 0.04) ( Table 3) .
comorbidity and cetuximab treatment duration
Patients with comorbidity on cetuximab were treated longer (median duration of treatment = 15.6 weeks for CCI ‡1 versus 8 weeks for CCI = 0; P = 0.06) and received higher total doses of cetuximab (median cumulative dose = 3508 mg/m 2 for CCI ‡1 versus 2152 mg/m 2 for CCI = 0; P = 0.06).
progression-free survival and tumor response
In MVA, site of primary in both colon and rectum (P = 0.008), 2 years or longer from initial diagnosis to randomization (P < 0.0001), wild-type K-ras status (P < 0.0001) and cetuximab treatment (P < 0.0001) were significantly associated with better progression-free survival. No significant association was found between either age or comorbidity score and progression-free survival. Two years or longer from initial diagnosis to randomization (P = 0.01) and wild-type K-ras status (P = 0.02) were significantly associated with higher response rate. No significant association was found between either age or comorbidity score and response rate.
age and comorbidity as biomarkers of benefit from cetuximab
The magnitude of treatment effect on OS was similar in the two age groups [HR 0.77 (95% CI 0.61-0.98) for cetuximab versus BSC for patients <65 years and HR 0.75 (95% CI 0.56-1.00) for patients ‡65 years]. Patients with higher comorbidity scores tended to have stronger treatment effects on OS [HR 0.80 (95% CI 0.65-0.99) for cetuximab versus BSC for patients with comorbidity 0 and HR 0.61 (95% CI 0.42-0.90) for patients with comorbidity score ‡1]. However, the interaction between treatment and comorbidity was not statistically significant (P = 0.21).
age and comorbidity and toxicity
Elderly patients (65 years or older) had significantly less grade 3 or 4 worse vomiting (1.8% versus 7.9%, P = 0.034) but more dyspnea (24.5% versus 11.2%, P = 0.005). Patients with higher CCI scores had significantly less grade 3 or 4 vomiting (0% versus 7.1%, P = 0.002) but more non-neutropenic fever (23.8% versus 9.8%, P = 0.005) ( Tables 4 and 5 ). discussion Significant research effort has been directed at establishing factors that predict the outcome of patients treated for metastatic colorectal cancer. In this exploratory analysis of the CO.17 clinical trial, we aimed to elucidate the potential for age, PS and comorbidity to predict the outcome of previously treated patients with metastatic colorectal cancer randomly assigned to further treatment with cetuximab or BSC. In this analysis, age was not associated with OS. Lack of an association between age and efficacy of treatment of malignant disease has been previously demonstrated [8, 14, 16, 29] and our results are consistent with that literature. Similarly 12.0 44 19 14.0 22 13 16.0 14 10 18.0 6 6 20.0 4 1 Figure 2 . Kaplan-Meier curves for overall survival by comorbidity groups, log-rank P = 0.047.
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Annals of Oncology concordant with prior studies was the finding that better PS was associated with improved OS in both univariate analysis and MVA [16, [30] [31] [32] [33] .
More surprisingly, and opposite to what might be expected, greater comorbidity in this study was associated with improved survival compared with those with fewer comorbidities in Comorbidity has proven to be difficult to define and measure accurately [20, 22] . However, as measured by the well-validated and extensively applied CCI, comorbidity has been shown to be an independent predictor of outcome (although with the association in the opposite direction to that in our study) in previous studies [25, 29, 34, 35] .
While counterintuitive, we hypothesize two possible explanations: clinicians may confuse comorbidity and PS, inappropriately downgrading the PS in those patients who have significant comorbidity. Thus, patients with significant comorbidity on CO.17 may have had a better PS than actually attributed. With PS as a dominant prognostic indicator, these patients would have had superior outcomes. The CCI was developed using hospitalized patients who predominantly would have an ECOG PS score of 3 or 4. Based on our results, PS is not correlated with comorbidity, which is in keeping with previous research [29, 33, 36] and with the analysis by Wedding et al. [37] . They were able to demonstrate the independent effects of PS and comorbidity (as measured by the Cumulative Illness Rating Scale) on quality of life in their study of hospitalized elderly cancer patients. The distinction between comorbidity and PS is critical but not always easy to make. As noted by Hall [38] '. A co-morbidity index is not an assessment of the impact of all illnesses on the overall health of a patient. These are performance scales . or functional assessment scales. These scales include the disease of interest (and its impact) and therefore have the same score for each patient regardless of the disease of interest.' [38] .
A second possible explanation for our results is that a yet to be determined factor (e.g. concomitant medication) administered frequently in patients with comorbidity may enhance efficacy of cetuximab. These hypotheses should be evaluated in future studies. The development and prospective validation of a comorbidity index specifically for ambulatory cancer patients may also help to clarify the impact of comorbid conditions on outcomes in oncology.
Even if the significant association between comorbidity and OS was lost in MVA, the trend contradicts the findings of prior studies, where greater comorbidity scores were associated with worse OS. The discrepancy between this study and prior studies may be the result of the population studied here. These patients had all been extensively pretreated and were highly selected; only one-quarter had comorbidities at randomization and only 4% had a CCI score of ‡2. This was, therefore, a homogenous population in terms of overall health status that would make it more difficult to show an effect of comorbidity. In the analysis by Rieker et al. [25] , two-thirds of patients had CCI scores between 0 and 2 while one-third of patients had scores of >2. They showed that greater comorbidity was significantly correlated with shorter OS in patients who had undergone resection of colorectal cancer [25] . Analysis of the prognostic value of age and comorbidity in the treatment of non-small-cell lung cancer by Asmis et al. showed that greater comorbidity was associated with shorter OS in a heterogenous population of previously untreated patients (31% of whom had CCI scores of >1) receiving either adjuvant or palliative systemic therapy [29] .
The definition of elderly is a topic of debate. In this study, elderly was defined as 65 years and older as this is the age segment of the population frequently used in epidemiologic studies and statistical reports [39] [40] [41] . Other studies have used 70 years or older as the definition of elderly [42, 43] and it is acknowledged that aging is an ongoing process, difficult to define by calendar age.
It is relevant to note that there were few differences in rates of serious adverse events between older and younger patients. Only dyspnea was significantly more frequent in the elderly, original article Annals of Oncology while vomiting was significantly more frequent in the younger population. Similarly, patients with greater comorbidity had significantly more non-neutropenic infection but significantly less vomiting than patients with lower comorbidity scores. VTE is a common complication of cancer and is more prevalent in patients receiving chemotherapy [44] . It is one of the leading causes of death in patients with cancer [45] and is associated with poor survival in patients with nongastrointestinal solid tumors [46] . In this study, 10% of patients had prior VTE. With such a high incidence of this complication for patients with colorectal cancer on chemotherapy, prophylactic anticoagulation should be investigated in future clinical trials.
The strengths of this analysis lie in the large number of patients included in a prospective study and the independent assessment of comorbidity by two physician investigators with high intraobserver agreement of comorbidity scoring. Limitations include the unplanned retrospective nature of the analysis and the homogeneity of the population studied in terms of level of comorbidity and extent of previous treatment.
While better PS is confirmed as a strong positive prognostic indicator for survival, the unexpected result that greater comorbidity trended toward superior OS compared with those with fewer comorbidities needs further exploration. This study has added to the body of knowledge demonstrating that treatment should not be decided based on age [14] [15] [16] [17] [18] [19] but should be considered in the context of each patient's overall PS. Physicians must carefully discriminate between PS and comorbidity when assessing patients for therapy. For patients with good PS, restricting cetuximab use in the setting of significant comorbidity does not appear justified. TRA has acted on advisory boards for Bristol Myers Squibb, CSK has acted on advisory board and has received honoraria for seminar presentation for Merck Serono, DJJ has acted on advisory boards and has received honoraria for seminar presentation for Bristol Myers Squibb, NP has acted on advisory boards and has received honoraria and travel funding and provided expert testimony for Merck Serono, CL is an employee of Bristol Myers Squibb and owns stock in Bristol Myers Squibb. 
